

For Immediate Release

Q3 2008

June 2008

AndroScience Corporation is selected to present at BIO 2008 Business Forum in San Diego to be held in June 2008; its President & CEO, Dr. Charles Shih, will give the presentation at the Forum.

NEW WEBSITE for AndroScience!

AndroScience Corporation is currently in the process of renovating its website and the new site is expected to be completed by the end of June, 2008.

A Phase 2 Clinical Trial in Acne Vulgaris is Expected to be Completed in the Summer of 2008

AndroScience Corporation has completed two phase 1 studies for its first topical drug indication, using ASC-J9 cream for acne vulgaris in April of 2007. A Phase 2 study - a randomized, double-blinded, placebo-controlled study - was started in September 2007. The purpose of this Phase 2 study is to evaluate the safety and efficacy of ASC-J9 cream as a topical treatment of acne vulgaris. This study is expected to be completed in the summer of 2008.

New IND Submission for Androgenetic Alopecia (AGA) Indication Using ASC-J9 Foam

AndroScience Corporation is also in the development of ASC-J9 as a topical treatment for androgenetic alopecia (AGA, or male pattern baldness). For this indication, ASC-J9 is being formulated into a new Foam formulation. A new IND for AGA indication, using ASC-J9 Foam, is expected to be submitted to the FDA in Q3 of 2008.

Q4 2008

Androgenetic Alopecia (AGA) Clinical Trials using ASC-J9 Foam

AndroScience Corporation is expected to start a Phase 2 clinical study in men with AGA, using topical ASC-J9 Foam, in Q4 of 2008.